St. Jude researchers found germline mutations in the transcription factor gene IKZF1 in 0.9 percent of presumed sporadic pediatric acute lymphoblastic leukemia cases.
The national PROFYLE study seeks to sequence tumor and matched normal samples from children and young adults with relapsed or treatment-resistant cancer.
St. Jude Cloud, powered by DNAnexus and Microsoft, offers free access to thousands of WGS records plus cloud-based visualization and computational tools.
California Kids Cancer Comparison leader David Haussler said the project's workflow was able to match 100 percent of tumor samples it tested to possible treatments.
A proportion of pediatric ALL patients appear to have germline TP53 mutations associated with later diagnoses, poorer outcomes, and increased secondary cancer risk.
New studies suggest low-, intermediate-, and high-methylation subgroups exist in juvenile myelomonocytic leukemia, potentially offering insights into patient outcomes.
A new consensus report suggests RB1 testing and genetic counseling to stratify risk and guide ophthalmic screening in kids with affected family members.
Genome and transcriptome sequences from hundreds of pediatric cancer cases led to somatic mutations and fusions suspected of producing potentially targetable antigens.
When investigators retraced recurrent mutations, expression changes, and methylation shifts in hundreds of Wilms tumor case, they identified two main pathways.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
